Life Sciences & Healthcare

LIFE SCIENCES & HEALTHCARE

Unlicensed Medicines

(effective planning and decisive action)

Assessed the opportunities in the face of major competitive threats to key products, re-structured and re-focused the business and coordinated a counter offensive strategy resulting in increasing profits by 50% in 2 years and cash reserves by 250% to enable a self-funded, secure development and marketing authorisation programme.

Consumer healthcare products

(from early stage to IPO, fund raising, risk management, investor relations)

Expanded from a single focus and underfunded position to multiple, parallel products in development and a series of funding rounds raising over £13 million (including an AIM listing) through considered strategic planning and forward thinking, innovative risk management, cost effectiveness and a structured investor relations programme.

Pharmaceutical tableting equipment

(Growth planning and structuring)

Devised strategy and business plan for sustainable and rapid expansion of novel, patented tablet testing equipment product and services provider in early stages of commercialisation to enable rapid growth within 5 years.

Novel biopharmaceuticals separations equipment

(Business planning, forecasting and re-organisation)

Restructuring and co-ordination of internal divisions to move focus from development to commercialisation and adoption of portfolio approach to clinical phase customers to enable faster growth for validated, disruptive chromatographic technology and allied services business.

Domiciliary Care

(Turnaround, improving cash flow and optimising operations)

Reversed the decline of an established provider of domiciliary care and live-in services to both state-funded and private clients by revising the operational model and identifying and addressing key impediments to re-establish growth at an annualised rate of over 30% p.a.

Neurodegenerative disorders

(Establishing systems, business planning, forecasts and “what if” risk analysis)

Establishing legal, taxation, financial controls and business planning and forecasting processes for University spin-out biotechnology company developing novel therapeutics and biomarkers for Alzheimer’s Disease and other neurodegenerative conditions.